Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc.
Your view on APGE
Overview
What the company does, where it operates, and who runs it.
About Apogee Therapeutics, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Michael Thomas Henderson
- Headquarters
- 221 Crescent Street, Waltham, MA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Michael Thomas Henderson
- Headquarters
- 221 Crescent Street, Waltham, MA, US
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications.
The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD.
The company was founded in 2022 and is based in Waltham, Massachusetts.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Apogee Therapeutics, Inc., and the rating behind it. APGE last traded at $135.07; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Apogee Therapeutics, Inc.. Starting points for Apogee Therapeutics, Inc.: EPS -$3.90, beta 0.34 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Apogee Therapeutics, Inc.. Apogee Therapeutics, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Apogee Therapeutics, Inc.. Trailing twelve-month EPS for Apogee Therapeutics, Inc. stands at -$3.90. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Apogee Therapeutics, Inc.. Apogee Therapeutics, Inc. has reported as a listed company since 2023. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Apogee Therapeutics, Inc. valued side by side against its closest peers. Apogee Therapeutics, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Apogee Therapeutics, Inc., and how their positions are changing. At a $8.36B market value, institutional positions materially move Apogee Therapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Apogee Therapeutics, Inc. executives and directors. Shares of Apogee Therapeutics, Inc. have traded between $26.20 and $67.57 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Apogee Therapeutics, Inc.. Apogee Therapeutics, Inc. is a $8.36B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Apogee Therapeutics, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Apogee Therapeutics, Inc.. Coverage tracks Apogee Therapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.